Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$88.67
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — ABT
Inflationary BoomStrengths
Operating Cash Flow: $9.6B (+11.8% YoY) — Operating cash flow grew 12% — the business generated more cash from day-to-day operations.
Gross Profit: $4.4B (+7.6% YoY) — Gross profit rose 8% — the spread between revenue and direct costs improved.
Total Assets: $86.7B (+6.5% YoY) — Total assets grew 7% — the company's resource base expanded.
Weaknesses
Net Income: $6.5B (-51.3% YoY) — Profit fell 51% but remained positive.
EPS (Diluted): $3.72 (-51.3% YoY) — Earnings per share fell 51%.
Opportunities
No clear opportunities identified at this time.
Threats
Net income dropped 51% year-over-year — a significant compression in profitability.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Net Income
$6.5B
was $13.4B
Profit fell 51% but remained positive.
EPS (Diluted)
$3.72
was $7.64
Earnings per share fell 51%.
Operating Cash Flow
$9.6B
was $8.6B
Operating cash flow grew 12% — the business generated more cash from day-to-day operations.
Gross Profit
$4.4B
was $4.1B
Gross profit rose 8% — the spread between revenue and direct costs improved.
Total Assets
$86.7B
was $81.4B
Total assets grew 7% — the company's resource base expanded.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Net income dropped 51% year-over-year — a significant compression in profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubFiling History — ABT
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade ABT
Links open broker research pages. Not an endorsement or recommendation.
Research ABBOTT LABORATORIES
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.